HC Wainwright Issues Positive Forecast for COGT Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Investment analysts at HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for Cogent Biosciences in a note issued to investors on Tuesday, May 20th. HC Wainwright analyst R. Burns now forecasts that the technology company will earn ($0.58) per share for the quarter, up from their previous forecast of ($0.66). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences’ Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.24) EPS and FY2026 earnings at ($2.09) EPS.

Other equities analysts have also issued reports about the company. Needham & Company LLC reissued a “hold” rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Robert W. Baird lowered their price objective on Cogent Biosciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 7th. Scotiabank started coverage on Cogent Biosciences in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $17.00 price objective on the stock. Piper Sandler upgraded Cogent Biosciences to a “strong-buy” rating in a research report on Friday, March 7th. Finally, Wedbush reiterated a “neutral” rating and issued a $11.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, February 25th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Cogent Biosciences Trading Down 2.6%

Shares of NASDAQ COGT opened at $4.82 on Thursday. The stock has a fifty day simple moving average of $5.18 and a two-hundred day simple moving average of $7.30. Cogent Biosciences has a 1-year low of $3.72 and a 1-year high of $12.61. The firm has a market cap of $548.79 million, a price-to-earnings ratio of -1.94 and a beta of 1.91.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Tuesday, May 6th. The technology company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.04.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. CWM LLC increased its holdings in shares of Cogent Biosciences by 11,869.9% in the first quarter. CWM LLC now owns 8,738 shares of the technology company’s stock worth $52,000 after buying an additional 8,665 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in shares of Cogent Biosciences in the fourth quarter worth about $78,000. Hsbc Holdings PLC bought a new stake in shares of Cogent Biosciences in the fourth quarter worth about $81,000. KLP Kapitalforvaltning AS purchased a new position in Cogent Biosciences during the 4th quarter valued at about $88,000. Finally, E Fund Management Co. Ltd. purchased a new position in Cogent Biosciences during the 4th quarter valued at about $89,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.